MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon
Published in Dutch archives.
<p xmlns=”http://www.w3.org/1999/xhtml”>NYON, <span class=”xn-location”>Switzerland, <span class=”xn-chron”>June 30, 2020 /PRNewswire/ — MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for…
Go to Source